Stock Events

Stock Events

Karyopharm Therapeutics 

€6.3
50
+€0.9+16.67% Today

Statistics

Day High
6.3
Day Low
6.3
52W High
8.4
52W Low
3.18
Volume
-
Avg. Volume
-
Mkt Cap
115.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-4.81
-3.61
-2.41
-1.21
Expected EPS
-1.21245086508
Actual EPS
N/A

Financials

-133.75%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
250.98MRevenue
-335.7MNet Income

Analyst Ratings

$11.84Average Price Target
The highest estimate is 21.25.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 25K0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Karyopharm's focus on cancer therapeutics.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences has a strong presence in the oncology and hematology market, directly competing with Karyopharm's cancer drug offerings.
AMGEN
AMGN
Mkt Cap187.56B
Amgen has a diverse range of cancer drugs that compete with Karyopharm's therapies in multiple myeloma and other cancers.
Merck
MRK
Mkt Cap298.84B
Merck & Co. is a leading pharmaceutical company with a strong lineup of cancer drugs that compete with Karyopharm's products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad oncology portfolio, including treatments for conditions that Karyopharm's drugs target.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the oncology market with a focus on cancer treatments, including therapies that could be in direct competition with Karyopharm's products.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca has a significant presence in the oncology sector, with drugs that compete against Karyopharm's offerings in cancer treatment.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a wide range of cancer treatments, including therapies that directly compete with Karyopharm's products.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, has a portfolio of cancer drugs that compete with Karyopharm's therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, though more focused on biotechnology, has been expanding its oncology portfolio, potentially competing with Karyopharm's cancer treatments.

About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Show more...
CEO
Mr. Richard A. Paulson M.B.A.
Employees
228
Country
DE
ISIN
US48576U2050
WKN
000A40YLC

Listings

F
DE
25K0.F
BOATS
BOATS
KPTI.BOATS
XNAS
US
KPTI

0 Comments

Share your thoughts

FAQ

What is Karyopharm Therapeutics stock price today?▼
The current price of 25K0.F is €6.3 EUR — it has increased by +16.67% in the past 24 hours. Watch Karyopharm Therapeutics stock price performance more closely on the chart.
What is Karyopharm Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Karyopharm Therapeutics stocks are traded under the ticker 25K0.F.
Is Karyopharm Therapeutics stock price growing?▼
25K0.F stock has risen by +32.35% compared to the previous week, the month change is a -16% fall, over the last year Karyopharm Therapeutics has showed a +80% increase.
What is Karyopharm Therapeutics market cap?▼
Today Karyopharm Therapeutics has the market capitalization of 115.57M
When is the next Karyopharm Therapeutics earnings date?▼
Karyopharm Therapeutics is going to release the next earnings report on April 30, 2026.
What were Karyopharm Therapeutics earnings last quarter?▼
25K0.F earnings for the last quarter are -4.81 EUR per share, whereas the estimation was -1.68 EUR resulting in a -186.32% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Karyopharm Therapeutics revenue for the last year?▼
Karyopharm Therapeutics revenue for the last year amounts to 250.98M EUR.
What is Karyopharm Therapeutics net income for the last year?▼
25K0.F net income for the last year is -335.7M EUR.
How many employees does Karyopharm Therapeutics have?▼
As of April 08, 2026, the company has 228 employees.
When did Karyopharm Therapeutics complete a stock split?▼
The last stock split for Karyopharm Therapeutics was on February 26, 2025 with a ratio of 1:15.
Where is Karyopharm Therapeutics headquartered?▼
Karyopharm Therapeutics is headquartered in Newton, DE.